

## MIRA INFORM REPORT

<b>Report No. :</b>	540427
<b>Report Date :</b>	23.11.2018

### IDENTIFICATION DETAILS

<b>Name :</b>	U.S. PHARMA LAB INC.
<b>Registered Office :</b>	1300 Airport Road ,North Brunswick,Nj,08902 Usa
<b>Country :</b>	United States
<b>Financials (as on) :</b>	2017 (summarized)
<b>Date of Incorporation :</b>	1996
<b>Legal Form :</b>	Corporation
<b>Line of Business :</b>	Subject designs, manufactures, and markets vitamin and supplement ingredients such as amino acids, botanical extracts, and minerals.
<b>No. of Employees :</b>	130 (Over 600 Globally)

**RATING & COMMENTS**

(Mira Inform has adopted New Rating mechanism w.e.f. 23<sup>rd</sup> January 2017)

**MIRA's Rating :**

A

Credit Rating	Explanation	Rating Comments
A	Acceptable Risk	Business dealings permissible with moderate risk of default

<b>Status :</b>	Good
<b>Payment Behaviour :</b>	Regular
<b>Litigation :</b>	Clear

**NOTES :**

Any query related to this report can be made on e-mail : [infodept@mirainform.com](mailto:infodept@mirainform.com) while quoting report number, name and date.

**ECGC Country Risk Classification List**

Country Name	Previous Rating (30.06.2018)	Current Rating (30.09.2018)
United States	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**UNITED STATES - ECONOMIC OVERVIEW**

The US has the most technologically powerful economy in the world, with a per capita GDP of \$59,500. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.

In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.

Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.

The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.

Imported oil accounts for more than 50% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at \$840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.

The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a \$700 billion Troubled Asset Relief Program in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and former President Barack OBAMA signed a bill providing an additional \$787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.

Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through FY 2018, the direct costs of the wars will have totaled more than \$1.9 trillion, according to US Government figures.

In March 2010, former President OBAMA signed into law the Patient Protection and Affordable Care Act (ACA), a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016,

through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.

In July 2010, the former president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.

The Federal Reserve Board (Fed) announced plans in December 2012 to purchase \$85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed ended its purchases during the summer of 2014, after the unemployment rate dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of GDP. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With continued low growth, the Fed opted to raise rates several times since then, and in December 2017, the target rate stood at 1.5%.

In December 2017, Congress passed and President Donald TRUMP signed the Tax Cuts and Jobs Act, which, among its various provisions, reduces the corporate tax rate from 35% to 21%; lowers the individual tax rate for those with the highest incomes from 39.6% to 37%, and by lesser percentages for those at lower income levels; changes many deductions and credits used to calculate taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do not obtain the minimum amount of health insurance required under the ACA. The new taxes took effect on 1 January 2018; the tax cut for corporations are permanent, but those for individuals are scheduled to expire after 2025. The Joint Committee on Taxation (JCT) under the Congressional Budget Office estimates that the new law will reduce tax revenues and increase the federal deficit by about \$1.45 trillion over the 2018-2027 period. This amount would decline if economic growth were to exceed the JCT's estimate.

Source : CIA

## **STATUTORY INFORMATION**

Legal Name	U.S. PHARMA LAB INC.
Trade Name	U.S. PHARMA LAB INC.
ID	ID
ID Details	0100785033
Creation Date	1996
Incorporation Date	06/18/1999
Legal Address	1300 AIRPORT ROAD ,NORTH BRUNSWICK,NJ,08902 USA
Operative Address	1300 AIRPORT ROAD, NORTH BRUNSWICK, NJ, 08902 USA
Telephone	732-296-1990
Fax	732-296-1922
Legal Form	CORPORATION
E-Mail	inquiry@uspharmalab.com
Registered In	NEW JERSEY
Website	www.uspharmalab.com
Contact	Ashok Luhadia, Founder & President
Staff	130 (over 600 globally)
Activity	NAICS Code: 424210, Drugs and Druggists' Sundries Merchant Wholesalers

## **BANKS**

Name of Bank	Reported Amount
BANK OF AMERICA	

## **HISTORY**

History

The company was founded in 1996 by Ashok Luhadia.

Key Developments

ProBiotix Health Ltd Enters Manufacturing and Supply Agreement with US Pharma Lab Inc

Oct 9 18

OptiBiotix Health plc announced that it has entered into a manufacturing and supply agreement with US Pharma Lab Inc. ("USPL"). This is the first agreement completed through its newly formed subsidiary ProBiotix Health Ltd, as previously announced on September 24, 2018. USPL has a strong reputation and leading expertise in developing unique formulations and presentations containing probiotic strains for the nutraceutical marketplace. Under the terms of the agreement, USPL is granted non-exclusive rights to manufacture and supply formulations containing OptiBiotix's LPLDL strain. It is an important step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's expertise and market reach to create multiple product opportunities to serve consumer healthcare and pharmaceutical markets around the world.

Parent Company

NA

## **PRINCIPAL ACTIVITY**

General Description

U.S. PHARMA LAB INC. designs, manufactures, and markets vitamin and supplement ingredients such as amino acids, botanical extracts, and minerals.

Service/Product Description

The company offers herbals, minerals, vitamins, amino acids, and specialty dietary supplements.

Sales

Wholesale

Operations Area

National and International

Imports From

INDIA

Employees

130 employees (over 600 globally)

Payments with Suppliers

Regular

Brands

Brand

Comments

US PHARMA LAB -

**Clients**

Name of Client	Country	Comments
----------------	---------	----------

There are no informed clients

Comments	It offers products to pharmaceutical and nutraceutical markets worldwide.
----------	---

**Suppliers**

Supplier Name	Country	Comments
---------------	---------	----------

AMOL PHARMACEUTICALS PVT., LTD.	INDIA	-
---------------------------------	-------	---

AMOL BIOTECH LTD.	INDIA	-
-------------------	-------	---

BECTOCHEM LOEDIGE PROCESS TECHNOLOGY PVT. LTD.,	INDIA	-
---	-------	---

Comments	-
----------	---

## **LOCATION**

Headquarters	1300 AIRPORT ROAD, NORTH BRUNSWICK, NJ, 08902 USA
--------------	---

Branches	No branches found.
----------	--------------------

## **GROUP STRUCTURE AND SUBDIARY COMPANIES**

Listed at the stock exchange	NO
------------------------------	----

Capital	NA
---------	----

Shareholders (%)	The company does not disclose information on shareholders. The following information has been provided by private sources:
------------------	--

Management	The major holder of this company is Ashok Luhadia. Ashok Luhadia, Founder & President Amol Luhadia, Executive Vice President Edward Keenan, VP of Sales Sandeep Sapra, VP of International Business Michael Richtmyer, General Manager
------------	---

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Subsidiary Companies

Dr. Som Ghatak, Director of Research & Development  
Ritesh Patel, Director of Research & Development  
Alka Kapoor, Director of QA/QC  
Uspl Nutritionals, LLC  
1300 AIRPORT RD  
NORTH BRUNSWICK, NJ, 08902-1795 United States

Related Companies

Ameripharma Labs Limited Liability Company  
1300 AIRPORT RD  
NORTH BRUNSWICK, NJ, 08902-1795 United States  
US PHARMA LAB INDIA  
(Amol Pharmaceuticals)  
E-362-363-364,  
Sitapura Industrial Area,  
Sanganer, Jaipur-302022 (Rajasthan), India

US PHARMA LAB CHINA  
(Amol Biotech)  
8138 Daye Road,  
Punan Machinery &  
Electronics Industrial Park,  
Fengcheng Town,  
Fengxian District,  
Shanghai 201409, China

**FINANCIAL INFORMATION**

General Description	The company does not make its financial statements public. The following information has been provided by private sources
Year/Currency	USD 2017
Sales	57.000.000
Money Flow	Normal
Import Fob Dollar Year	Amount
There are not Import Fob Dollar informed	
Export Fob Dollar Year	Amount
There are not Export Fob Dollar informed	

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

## **LEGAL FILINGS**

Lawsuits	No records found.
Trademarks	US PHARMA LABS manufacturing dietary supplements Owned by: U S Pharma Labs, Inc. Serial Number: 75886662 No records found.
Patents Registered	
Renewals	Annual Report Month: JUNE Last Annual Report Filed: 04/19/2018 Year: 2018 No records found.
UCC (Uniform Commercial Code)	No records found.
OFAC Sanctions List Search	The company is not listed in the OFAC Sanctions List.

## **SUMMARY**

Summary	Founded in 1996, US PHARMA LAB INC. is an organization in the Drugs and Druggists' Sundries Merchant Wholesalers Industry headquartered in North Brunswick, NJ. The company has 130 regular employees and generates an estimated USD\$57 million in annual revenue. It operates nationally, mainly importing from India. It is ACTIVE in business with no negative records.
---------	---

## **RISK INFORMATION**

Debts	Controlled
Payments	Regular
Cash Flow	Normal
State	Active



**MIRA INFORM PRIVATE LIMITED**  
605, Palmspring, Near D'Mart, Link Road,  
Malad (West), Mumbai - 400 064. INDIA  
Tel : 91-22-40448000 (44 lines)  
Fax : 91-22-40448045 / 40448046  
E-mail : mira@mirainform.com  
info@mirainform.com  
Website : <http://www.mirainform.com>  
<http://www.miraglobalcheck.com>  
<http://www.miraglobalcollections.com>

## **INTERVIEW**

First Name	Madak
Position	-
Comments	She confirmed the name of the company, the address of the headquarters and location, the date of creation of the company, the company's website and email, the approximate number of employees and the name of the President.

**FOREIGN EXCHANGE RATES**

Currency	Unit	Indian Rupees
US Dollar	1	INR 71.90
UK Pound	1	INR 92.19
Euro	1	INR 81.94
USD	1	INR 70.67

**Note** : Above are approximate rates obtained from sources believed to be correct

**INFORMATION DETAILS**

Analysis Done by :	VIVR
Report Prepared by :	POJ

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**RATING EXPLANATIONS**

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)